SITE001-0346

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE001 (USA) (Dr. Reyes) · consented 2023-04-18

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

mild assessed 2026-08-18

Grade 1 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 34); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Rash — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 119); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-07 (study day 197); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-25 (study day 336); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-03-27 (study day 338); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-06-10 (study day 413); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Thrombocytopenia — outcome: UNKNOWN; onset 2024-06-29 (study day 432); relationship: N; serious criteria: life-threatening

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.